David Jarjoura PhD

David Jarjoura PhD
Research ProfessorCollege of Public HealthDavid.Jarjoura@osumc.edu
Center for Biostatistics 2012 Kenny Road Columbus OH 43210
Phone:614-293-6471Fax: 614-293-6902
  • Non-Member

Current Publications

  • Ma Y, McCarty SK, Kapuriya NP, Brendel VJ, Wang C, Zhang X, Jarjoura D, Saji M, Chen CS, Ringel MDDevelopment of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.J Clin Endocrinol Metab 98(8) E1314-22 8/1/2013
  • Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson K, Jarjoura D, Blum W, Marcucci G, Caligiuri MAToward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.Leukemia in press 5/10/2013
  • Mao Y, Triantafillou G, Hertlein E, Towns WH, Stefanovski M, Mo X, Jarjoura D, Phelps MA, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, John BC, Muthusamy NMilatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.Clin Cancer Res 19(2) 347-56 1/15/2013
  • Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy NTargeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.Blood 121(1) 136-47 1/3/2013
  • Rozewski DM, Herman SE, Towns WH 2nd, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D, Byrd JC, Johnson AJ, Phelps MAPharmacokinetics and tissue disposition of lenalidomide in mice.AAPS J 14(4) 872-82 12/1/2012
  • Henry JC, Pouly S, Sullivan R, Sharif S, Klemanski D, Abdel-Misih S, Arradaza N, Jarjoura D, Schmidt C, Bloomston MA scoring system for the prognosis and treatment of malignant bowel obstruction.Surgery 152(4) 747-56; discussion 756-7 10/1/2012
  • Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn D, Baiocchi R, Grever MR, Lucas DMDual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Clin Cancer Res 18(17) 4600-11 9/1/2012
  • Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG, Yanes DA, McConnell KK, Mao C, Kalu C, Zhang X, Jarjoura D, Dorrance AM, Heerema NA, Lee BH, Huang G, Marcucci G, Caligiuri MAMll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.Blood 120(5) 1130-6 8/2/2012
  • El-Elimat T, Zhang X, Jarjoura D, Moy FJ, Orjala J, Kinghorn AD, Pearce CJ, Oberlies NHChemical Diversity of Metabolites from Fungi, Cyanobacteria, and Plants Relative to FDA-Approved Anticancer Agents.ACS Med Chem Lett 3(8) 645-649 7/12/2012
  • Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JCXmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.Leukemia 26(7) 1720-2 7/1/2012
  • Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JCTetraspanin CD37 directly mediates transduction of survival and apoptotic signals.Cancer Cell 21(5) 694-708 5/15/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu